ABSTRACT: Background. Adenoid cystic carcinoma (ACC) of the head and neck is a rare but highly malignant tumor. Cancer-testis antigens (CTAs) represent an immunogenic family of cancer-specific proteins and thus represent an attractive target for immunotherapy. Methods. Eighty-four cases of ACC were identified, the CTAs panMelanoma antigen (pan-MAGE; M3H67) and New York esophageal squamous cell carcinoma (NY-ESO-1; E978) were detected immunohistochemically (IHC) and correlated with clinical data. 
INTRODUCTION
Adenoid cystic carcinoma (ACC) of the head and neck is a rare malignant tumor that often occurs in the major salivary glands, although occurrence in the minor salivary glands, the palate, base of tongue, paranasal sinuses, and all other head and neck sites combined is more frequent. Primary therapy consists of radical surgery, and adjuvant radiotherapy is added in cases of nodal involvement, advanced stage, or close resection margins. 1 Locoregional recurrences because of perineural invasion (PNI), or distant failure most often because of lung metastases, result in poor long-term prognosis. Available chemotherapeutics and targeted agents have shown little effect on this slowly but relentlessly growing entity. 2, 3 This, along with the recent success of immunotherapy in other tumor types, makes identification of new immunotherapeutic targets of significant interest in this disease.
Cancer testis antigens (CTAs) represent an immunogenic family immunogenic family of proteins that are expressed physiologically in germ-line tissue, but also in certain malignant tumors. In adult patients, CTA expression is highly cancer-specific. Previous studies from Park et al 4 in 2012 indicate that MAGE can be useful in the differentiation of pleomorphic adenoma and adenoid cystic carcinoma because MAGE was expressed in a very high percentage of the tested samples, whereas it was not detected in adenomas at all. The clinical impact of CTA expression in ACC has not been investigated so far. In head and neck squamous cell carcinoma (HNSCC) on the other hand, CTAs of the MAGE-family and New York esophageal squamous cell carcinoma (NY-ESO-1) have been identified as an independent marker for poor overall survival (OS). 5 Because of the high specificity and immunogenicity of these antigens, immunotherapy seems to be a promising approach. Several vaccination trials against NY-ESO-1, another CTA, show the first positive therapeutic effects in different solid tumors. [6] [7] [8] The purpose of this study was to determine the incidence of CTA expression in ACC as a potential target for specific immunotherapy. A secondary purpose was the evaluation of CTA expression as a prognostic marker.
MATERIALS AND METHODS
Eighty-four cases of ACC with available clinical data and paraffin-embedded tissue were identified. The study was endorsed by the local ethics committee (Ethikkommission Ulm, number 304/13) and the institutional review board. Demographic and clinical data were obtained from the electronic health record and pseudonymized. Perineural invasion (PNI), positive resection margins (R1), and histological growth pattern (solid, tubular, cribriform, and mixed) were determined in the surgical specimen of the initial resection.
OS was calculated from the time of diagnosis until the time of death and progression-free survival (PFS) was calculated from time of diagnosis -whichever occured first.
Immunohistochemistry
The 3-lm thick sections were cut from paraffinembedded tissue. After deparaffinization in xylene and descending alcohol grades, heat-induced antigen retrieval was obtained using a steam cooker (Multi Gourmet; Braun, Germany) for 20 minutes with 1 mM EDTAbuffer (pH 8.0). TRIS-buffered saline-Tween-20 (TBST)-bath was used as washing buffer. After encircling the specimens with the Dako Pen (Dako, Glostrup, Denmark), the slides were treated by Dako EnVision1 Systemhorseradish peroxidase (Dako) for use with primary mouse antibodies (Dako). Peroxidase block was used for 5 minutes, followed by a protein block (serum-free, "Ready-To-Use;" Dako) for 10 minutes. Subsequently, the samples were incubated with the primary antibodies for 30 minutes. After antibodies and dilutions were used: NY-ESO-1 (E978) 1:200; pan-melanoma antigen E (pan-MAGE; M3H67) 1:1000, both antibodies were provided by Dr. Gerd Ritter the New York Branch of the Ludwig Institute for Cancer Research (New York, NY). Antigen specificity of the above antibodies has been described previously. 5 Subsequently, after washing twice with TBST-buffer (5 minutes each), the secondary antibody conjugated with a horseradish peroxidase labeled polymer was applied for 30 minutes. After another TBST-buffer bath (5 minutes), the samples were incubated with 3,3 0 -diaminobenzidine chromogene (preparation of 1-mL substrate buffer and 1 drop diaminobenzidine-chromogene; Dako) for 15 minutes. Counterstaining was obtained with hematoxylineosin stain (Mayer's hematoxylin solution; SigmaAldrich, Chemie GmbH, Steinheim, Germany). The samples were fixated by Aquatex (Merck, KGaA, Darmstadt, Germany) and cover glasses.
Human testis specimens served as positive controls. Healthy human mucosal tissue (tongue) and parotid tissue from voluntary donors who underwent surgery for parotid adenoma was used for negative controls.
Interpretation of stained slides was done by light microscopy. All slides were evaluated by 3 independent experienced specialists and blinded control was done by a consultant of the pathology department.
A well-established immunohistochemical (IHC) staining score was gathered from staining intensity and fraction of positive tumor cells. The staining intensity was evaluated separately in nuclear and cytoplasmatic staining and was scored as follows: 0 5 no staining; 11 5 weak staining; 21 5 mild staining; and 31 5 strong staining. Furthermore, the percentage of stained cells was scored from 0-100%. The final score was defined as "negative" if 
RESULTS

Patient cohort
All 84 patients underwent surgery, the majority (66 of 84) received adjuvant radiotherapy. Thirty-eight of 84 tumors (45.2%) were localized in the major salivary glands, 26 of 84 (31%) of these were in the parotid, 9 of 84 (10.7%) were in the submandibular, and 3 of 84 (3.6%) were in the sublingual gland. Other primary sites were found in 46 of 84 (54.8%). These included the paranasal sinuses in 17 of 84 (21.4%), the palate in 8 of 84 (9.5%), the floor of the mouth in 4 of 84 (4.8%), and other localizations like the midface or lacrimal glands in 13 of 84 (15.5%). The subsites can be found in Table 1 . Median age at primary diagnosis was 54 years, 44 patients were women and 40 were men. Median PFS and OS were 36.1 and 82.3 months, respectively. Further patient characteristics can be found in Table 2 .
Prognostic markers
PNI was a highly significant prognosticator for OS. Median OS for PNI patients was 130.8 months, whereas in non-PNI patients median OS was not reached (p 5 .025; Figure 1A ). Median PFS for PNI versus non-PNI was 42 and 267.3 months, respectively (p 5 .039). Positive resection margins were associated with reduced OS (R1 5 105.3 months; R0 5 median OS not reached; p 5 .028; Figure 1B ), but did not significantly influence PFS (R1 5 39.5; R0 5 85.0 months; p 5 .103). Positive nodal status was associated with reduced OS (median OS not reached; p 5 .008; Figure 1C ), but did not significantly impact PFS (pN1: 30.3, pN0 5 86.8 months; p 5 .287). A primary tumor outside of the major salivary glands went along with reduced OS (major salivary gland primary 5 median OS not reached; other primary 5 122.5 months; p 5 .047; Figure 1D ). Differences in PFS were not significant (major salivary gland primary 5 83.3; other primary 5 42.0 months; p 5 .301). The site of treatment failure was another significant prognosticator. Distant failure compared with local and/or regional failure resulted in a reduced median OS of 81.3 versus 195.3 months, respectively (p 5 .003; Figure 1E ). PFS was not significantly different with 21 versus 27 months, respectively. Solid growth pattern of ACC is another parameter that is associated with reduced survival. We transformed the histologic growth pattern (tubular, cribriform, mixed, and solid) into a bivariate variable (nonsolid vs solid). OS was significantly reduced for solid compared to nonsolid tumors with 96.6 months compared to 190.1 months, respectively (p 5 .012), as shown in Figure 1F . PFS difference did not reach significance with 59.5 months and 125.4 months, respectively (p 5 .086).
PNI was significantly correlated with positive resection margins (p < .0001) and a primary site outside of the major salivary glands (p 5 .02). Positive resection margins were also correlated with a primary site outside of the major salivary glands (p 5 .036). Positive lymph node status and the site of treatment failure were not correlated with any of the other clinical parameters. A solid growth pattern was significantly associated with treatment failure at distant/multiple sites (p 5 .024).
Immunohistochemical expression of cancer-testis antigens
Positive staining was exclusively observed in tumor cells, not in nontumoral surrounding tissue or negative controls. IHC staining showed NY-ESO-1 expression in 48 of 84 patients (57.1%). According to the IHC-score described in the Methods section, weak staining intensity was found in 28 of 84 patients (43.5%), moderate staining in 12 of 84 (14.3%), and strong intensity in 7 of 84 (8.3%).
Pan-MAGE positivity was observed in 28 of 84 patients (31.2%). According to the IHC score, a weak staining intensity was found in 12 of 84 (14.3%), moderate intensity in 11 of 84 (13.1%), and strong intensity in 5 of 84 (6.0%). Representative staining examples for NY-ESO-1 and pan-MAGE are presented in Figures 2 and 3 , respectively. 
Prognostic impact of cancer-testis antigens expression
Using the chi-square test and a Pearson correlation, we found that NY-ESO-1 expression was more frequent in primary sites other than the major salivary glands (p 5 .037; Table 3 ). Pan-MAGE expression was more frequent in patients with positive lymph nodes (p 5 .045; Table 3 ).
Median OS in NY-ESO-1 positive patients was 130.8 months compared with 282.0 months (p 5 .223) in patients lacking NY-ESO-1 expression ( Figure 4A ). In NY-ESO-1 positive patients, PFS was 66.3 compared with 88.3 months in negative cases (p 5 .507; Figure 4B ).
Median OS in pan-MAGE positive patients was 105.3 months compared with 190.5 months in negative patients (p 5 .096; Figure 4C ). Median PFS was 52.8 months compared with 76.0 months in pan-MAGE negative cases (p 5 .572; Figure 4D ).
Patients expressing both NY-ESO-1 and pan-MAGE simultaneously had significantly reduced survival with a median of 90.5 months compared with 282.0 months in negative patients (p 5 .047) and 190.5 months in patients either expressing only NY-ESO-1 or only pan-MAGE (p 5 .063). The survival difference between negative patients and NY-ESO-1 or pan-MAGE only patients was not statistically significant (p 5 .867). Survival curves are depicted in Figure 5 . There was no significant correlation to other prognostically relevant markers in this subset.
DISCUSSION
To our knowledge, this is the largest cohort of ACC that has been analyzed for CTA expression and its potential prognostic impact. Because of the low incidence of ACC, the gathering of relevant patient numbers and survival data are cumbersome and therefore requires a multiinstitutional approach.
In this retrospective study, we focused on the expression of CTAs in ACC. CTA expression is by definition restricted to malignant tumors and not found in normal tissues with the exception of testis and fetal placenta. The antibodies used (E978 for NY-ESO-1, and M3H67 for pan-MAGE) have been used by multiple groups for the detection of CTAs and are well-established for IHC.
5,9-13 IHC results have been reported to correspond well with mRNA analysis. 14 We have previously shown that M3H67 detects multiple MAGE-family antigens, but not control peptides. 5 A risk of false-positive staining cannot be excluded, but has not been reported for these antibodies. This is the first study analyzing the prognostic impact of CTA expression in ACC. Specimens were collected from 4 different treatment sites. Thus, it was possible to assemble a cohort of 84 patients with relevant follow-up and clinical data.
In order to determine the validity of our cohort, we analyzed known prognostic markers for OS, such as PNI, positive resection margins, positive lymph nodes, the primary tumor site, the pattern of treatment failure, and the histological growth pattern. All of these factors were, as expected, associated with worse outcome.
Furthermore, we determined that the site of the primary tumor was associated with OS. Patients with a primary tumor site other than the major salivary glands were more likely to be PNI and positive margin resection. Because of common anatomic proximity to fundamental structures, like the orbit and skull base, the most frequent other primary sites, such as the nasal sinuses, the midface, and the lacrimal glands with close proximity to such structures confront the treating surgeon with functional problems. This may explain the higher rate of positive resection margins at primary resection in this group of patients. Another reason may be the higher rate of PNI, which also reduces the probability of complete surgical resection. ACC is a rare but highly malignant disease that challenges the clinician in effective cancer therapy. Even in the case of successful primary surgery with curative intent, locoregional control is often unsatisfactory. Treatment failure, whether locoregional or distant, occurred in approximately 60% of our patient cohort, as also seen in the literature. If a disease relapse is nonresectable or occurs as distant metastasis, the treatment options for patients are very limited and include radiotherapy or systemic treatment, such as chemotherapy or the use of molecular targeting agents. For either of these options, treatment results from clinical trials have been frustrating. [1] [2] [3] Immunotherapy has the advantage of a systemic treatment potential that is independent of the site of failure. Recent developments in the field of immune checkpoint inhibition, especially in malignant melanoma (eg, CTLA-4 or PD-1/PD-L1 blockade) have moved immunotherapy into the spotlight. [15] [16] [17] [18] [19] [20] [21] [22] All these agents have 1 trait in common: they reconstitute the efficacy of preexisting immune responses in patients. Because immune checkpoint modulators are known to release the brake of the immune system, 23,24 the presence of an existing immune response is a necessary requirement for the success of such immune checkpoint modulators. Data from melanoma treated with immune checkpoint modulators suggest that a high mutational load is associated with a good clinical response to immune checkpoint blockade. 25 This is explained by a higher probability of mutations leading to the expression of so-called mutational neoantigens, which can be recognized by the immune system. [25] [26] [27] However, the average number of mutations found in adenoid cystic carcinoma is low compared with other cancer types. 2, 28, 29 The prevalence of neoantigens in ACC is yet unknown, but we demonstrate here a frequent expression rate of MAGE-family and NY-ESO-1 CTAs as potential immunologic targets. In the studies demonstrating immune responses to neoantigens in patients treated with immune checkpoint blockade, other nonmutational antigens, such as CTAs, were due to the methodology of the antigen screening process, neglected thus far. Nevertheless, the addition of an antigen-specific treatment in the form of a vaccine may increase the rate of responders to immune checkpoint targeted therapy. It has been shown that vaccines against MAGE-A3 30-34 as well as NY-ESO-1 can successfully induce the development of specific T-cell responses. [35] [36] [37] [38] Because of their high tumorspecificity and their immunogenicity, these antigens may represent a good target for specific immunotherapy of ACC. In patients with melanoma treated with ipilimumab, an increased rate of NY-ESO-1 specific immunity has been associated with improved clinical benefit of treatment, especially in patients developing both NY-ESO-1 specific antibodies and specific CD8 T cells. 39 A clinical trial with a multipeptide vaccine containing gp100, MART-1, and NY-ESO-1 with Montanide ISA 51 VG combined with nivolumab has been carried out in high-risk melanoma in an adjuvant setting and yielded an increase of antigen-specific CD8 T cells after treatment. 40 Because CTAs are to be considered self-antigens, spontaneous immune responses may be hampered by thymic tolerance. A detailed analysis of immune responses to CTA in ACC and immune modulatory components may help to identify a promising approach to reduce immunosuppression of CTA-specific immunity in ACC. The analysis of specific cellular immune responses and the tumor microenvironment may reveal which kind of immune checkpoint modulation could synergize with a vaccination approach in ACC.
Tumor-infiltrating immune cells are often discussed as a sign of immunologic recognition of the tumor. 41 Tumorinfiltrating immune cell have been shown to be important prognosticators in many cancer types, including colorectal cancer [42] [43] [44] [45] [46] and HNSCC. [47] [48] [49] [50] [51] The composition of tumorinfiltrating immune cell (different T-cell types, B cells, macrophages, and regulatory immune cells), their location (intratumoral, tumor margin, or tumor stroma), and density are all important factors. 42, 47, 52 There is still an intensive debate about which markers need to be measured, which tumor compartments to evaluate, and which method to use for quantification of tumor-infiltrating immune cells. Currently, there are no such data on tumor infiltrating immune cells available for ACC. This is an important task and will be the subject of a future project of our group.
In this patient cohort, NY-ESO-1 expression was found in 48 of 84 patients (57.1%) and pan-MAGE expression in 28 of 84 (31.2%). Our findings differ from the results of Park et al, 4 who described MAGE-A (dilution 1:200; Santa Cruz Biotechnology, Santa Cruz, CA) and MAGE-A4 (1:200; ABGENT, San Diego, CA) in 100% in a cohort of 31 cases of ACC of the parotid gland. One reason for this discrepancy may lie in the cutoff for CTA expression of 10% positive cells in our study and 1% in the work of Park et al. 4 Furthermore, the analysis of Park et al 4 was undertaken in a small cohort of 31 patients with ACC and solely parotid gland tumors were included. In a subgroup analysis of the 26 parotid tumors in our cohort, we found NY-ESO-1 in 12 of 26 and pan-MAGE in 8 of 26 patients.
In HNSCC, the expression of CTAs of the MAGEfamily and NY-ESO-1 have been determined as independent prognostic factors for poor survival. 5 The results from our data also show a trend toward worse OS in NY-ESO-1 and pan-MAGE positive patients, although this difference was not statistically significant. The trend to reduced survival in this cohort may be a result of the significant correlation with other prognostic markers. In the case of NY-ESO-1, it was the primary tumor site outside of the major salivary glands. Pan-MAGE expression was also associated with positive lymph node status. However, the simultaneous expression of NY-ESO-1 and pan-MAGE found in 20 patients was associated with significantly reduced OS and was not associated with other known prognosticators.
Another potential explanation for the reduced survival may lie in the intrinsic function of these proteins. CTA have been suggested to support malignant transformation by preventing apoptosis, 53, 54 or by the promotion of cell proliferation. 55, 56 Whereas the function of NY-ESO-1 in both healthy and malignant cells is still poorly characterized, the MAGE-family of proteins has previously been functionally analyzed. They also have been described to modify p53 function. 57, 58 Additionally, MAGE seems to promote DNA damage repair in malignant cells. 59 In summary, there is some evidence that CTA expression may promote malignancy and may be a sign of an aggressive tumor. It has been previously reported for HNSCC that the expression of more than 1 CTA is associated with reduced survival. 60 The high rate of CTA expression in ACC leads to more evidence for possible immunotherapeutic approaches in this entity. Before the conduction of clinical trials, further understanding of the specific immunological responses in the tumor and its microenvironment are mandatory. In order to conduct prospective clinical trials in this rare tumor entity, multicenter approaches of cancer centers are needed.
CONCLUSION
A significant fraction of patients with ACC show expression of the CTAs NY-ESO-1 and pan-MAGE. Positivity for both antigens simultaneously is associated with reduced OS. Thus, this subgroup of patients with a poor prognosis carries antigens targetable by specific immunotherapy. In recurrent and metastatic disease, trials of antigen-specific immunotherapy potentially combined with immunecheckpoint blockade seem warranted. In order to establish a strong rationale for this treatment approach, additional studies regarding the frequency of immune responses to these antigens and the most promising targets for immune checkpoint modulation are needed. 
